Purchase
Description
LUCENTIS® (ranibizumab) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by CHO expression system.
Ranibizumab is supplied at a concentration of 10 mg/mL as a sterile, colorless to pale yellow solution, which contains 10 mM histidine HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.
Properties
|
Name
|
Ranibizumab
|
|
CAS
NO.
|
347396-82-1
|
|
Type
|
Fab fragment
|
|
Source
|
Humanized (from mouse)
|
|
Target
|
VEGF-A
|
|
Clone
|
Monoclone
|
|
Molecular
Weight
|
48 kDa
|
|
Formula
|
C2158H3282N562O681S12
|
|
Antibody
Form
|
Purified immunoglobulin
|
|
Physical
Form
|
Solution
|
|
Grade
Standard
|
Medicine Grade
|
|
Place
of Origin
|
China(Mainland)
|
|
Storage
|
-70±15℃ for long-term
storage, 2-8℃ for short-term storage, away from light.
|
Supply Ability
20 kilogram per year, Minimum order quantity is 1 gram.
Price
Inquiry
Material Safety Data Sheet
If you need more information, please contact us.
Certificate Of Analysis
/en/UploadFile/file/201805/20180508154922582258.rar
Detail information about the product please refer the website below：
https://en.wikipedia.org/wiki/Ranibizumab
| 
